KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Share-based Compensation (2016 - 2025)

Nektar Therapeutics has reported Share-based Compensation over the past 16 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.2 million for Q4 2025, down 54.34% from a year ago — trailing twelve months through Dec 2025 was $12.6 million (down 41.47% YoY), and the annual figure for FY2025 was $12.6 million, down 41.47%.
  • Share-based Compensation for Q4 2025 was $2.2 million at Nektar Therapeutics, down from $3.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for NKTR hit a ceiling of $24.7 million in Q3 2021 and a floor of $2.2 million in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $8.1 million (2023), compared with a mean of $11.0 million.
  • Biggest five-year swings in Share-based Compensation: increased 4.18% in 2021 and later crashed 54.34% in 2025.
  • Nektar Therapeutics' Share-based Compensation stood at $22.4 million in 2021, then crashed by 43.15% to $12.7 million in 2022, then crashed by 43.05% to $7.3 million in 2023, then plummeted by 33.79% to $4.8 million in 2024, then crashed by 54.34% to $2.2 million in 2025.
  • The last three reported values for Share-based Compensation were $2.2 million (Q4 2025), $3.1 million (Q3 2025), and $3.5 million (Q2 2025) per Business Quant data.